Olanzapine — Zyprexa — is among the most effective antipsychotics available, especially for severe schizophrenia and acute mania. The CATIE trial showed it had the lowest discontinuation rate of the SGAs studied — patients on olanzapine were more likely to continue treatment, often because the drug simply worked when others didn't. But that effectiveness comes with a profile that has reshaped how olanzapine is used today.
- Class
- Second-generation antipsychotic
- Mechanism
- D2 + 5-HT2A + 5-HT2C + 5-HT6 + H1 + M1 + alpha-1 antagonism. Multi-receptor — one of the broadest profiles among SGAs.
- Typical dose
- Oral 5-20 mg/day; IM (acute agitation) 10 mg; LAI (Relprevv) 150-300 mg every 2-4 weeks
- Half-life
- ~30 hours
- FDA indications
- Schizophrenia, bipolar I (acute mania, maintenance), treatment-resistant depression (in combination with fluoxetine — Symbyax)
- Key adverse effects
- Substantial weight gain (often >7% body weight), metabolic syndrome, sedation, anticholinergic effects, orthostasis. Less EPS than risperidone. LAI: post-injection delirium/sedation syndrome (PDSS) — REMS required.
Black box: Increased mortality in elderly patients with dementia-related psychosis; post-injection delirium/sedation syndrome with LAI (REMS)
Often most effective SGA for severe schizophrenia and acute mania, but metabolic burden is the central clinical concern. CATIE: lowest discontinuation rate of SGAs studied. Weight gain often substantial within months — counsel and monitor. LAI form requires 3-hour observation due to PDSS.
The mechanism is one of the broadest in the SGA class: D2 antagonism, 5-HT2A, 5-HT2C, 5-HT6, H1, M1, alpha-1. The multi-receptor breadth produces strong antipsychotic effect — and substantial metabolic burden. Weight gain on olanzapine is often dramatic: 5-10 percent body weight in the first months, sometimes more. Lipid elevation. Glucose dysregulation. New-onset diabetes is a documented risk, sometimes emerging even before significant weight gain. For patients with metabolic risk, olanzapine is rarely first choice today.
Olanzapine is among the most effective SGAs and the most metabolically harmful — its broad receptor blockade delivers efficacy and metabolic syndrome together.
Mechanism note: Olanzapine forces an explicit efficacy-versus-metabolic trade-off. When chosen, the metabolic monitoring and often a metformin pairing are part of the prescription, not optional add-ons.
Several strategies mitigate the metabolic burden. Metformin co-prescription has evidence for reducing weight gain on olanzapine. Lifestyle intervention helps. The combination olanzapine + samidorphan (Lybalvi) is FDA-approved partly for weight gain attenuation — the opioid antagonist component appears to reduce the appetite effect. Lifestyle and pharmacologic mitigation can extend the time olanzapine remains tolerable, but the drug's metabolic signature is unavoidable for many patients.
Indications are broad: schizophrenia, bipolar I (acute mania and maintenance), treatment-resistant depression in combination with fluoxetine (Symbyax). The breadth and effectiveness make olanzapine indispensable for patients with severe illness where other agents have not worked.
Olanzapine LAI — Zyprexa Relprevv — has a unique adverse effect called post-injection delirium/sedation syndrome (PDSS). Roughly 0.07 percent of injections produce sudden severe sedation, delirium, sometimes coma. The mechanism is inadvertent intravascular delivery of the depot formulation. The REMS requires a 3-hour observation period after each injection. The infrastructure cost is real, and many practices have moved away from olanzapine LAI for this reason.
For severe psychosis or mania when other agents have not worked, olanzapine often is the answer despite the metabolic cost. The choice is deliberate, not default.